Pulmonary fibrosis in post-COVID-19: epithelial-mesenchymal transition as a key mechanism and target for therapy
- 8 December 2025
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (1) , 79-89
Abstract
Pulmonary fibrosis is a serious threat to global health, especially in after math of covid-19 infection, eventually results in fibrotic remodeling and organ damage. This SARS-CoV 2 induced fibrosis initiates cascade of proinflammatory responses such as cytokine release. EMT (Epithelial-mesenchymal transition) is a central event in post COVID 19 pulmonary fibrosis which is characterized by the accumulation of stimulated fibroblast and myoblast, finally epithelial morphology changed to mesenchymal traits. This transformation is marked by the loss of intercellular adhesion and polarity. A study of SARS-CoV 2 pathogenesis and EMT can provide insights to pulmonary fibrosis. Hence identification of biomarkers of EMT activation helps early diagnosis and determination of therapeutic approaches against pathogenesis. This review focusing on the mechanism of post-covid 19 pulmonary fibrosis through EMT with a special importance to TGF-β/Smad, NF-κB pathways and oxidative stress. Previous studies marked the EMT induced fibronectin, collagen deposition that can potentially disrupt lung structure and its function. SARS CoV 2 infection can trigger Hyper activation of profibrotic pathways like TGF-β/Smad, NF-κB pathways that maintain EMT via downregulation of E-Cadherin and upregulation of vimentin, fibronectin and α-SMA. SARS-CoV spike-protein binds to AEC-2 cells initiates cytokine storm followed by amplified NF-κB pathway, and oxidative stress. Elevated activation of this pathway increases Snail, Slug, Twist expression that leads to EMT. Moreover, increased ROS production creates fibrotic environment in lung. This review examined the mechanism behind the pulmonary fibrosis by analyzing interplay between the SARS-CoV 2 infection and EMT, providing effective therapeutic strategies to prevent EMT. Graphical abstractKeywords
Funding Information
- Indian Council of Medical Research (VIR/COVID-19/6/2021/ECD-I)
This publication has 101 references indexed in Scilit:
- Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathwayBiochemical Pharmacology, 2024
- The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanismsBiomedicine & Pharmacotherapy, 2024
- SARS‐CoV‐2 nucleocapsid protein enhances the level of mitochondrial reactive oxygen speciesJournal of Medical Virology, 2023
- Alpha-mangostin alleviate renal interstitial fibrosis via suppression of TGF-β1/Smad/ERK signaling axis in vitro and in vivoBiochemical Pharmacology, 2023
- Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cellsArchives of Biochemistry and Biophysics, 2023
- Geranylgeranylacetone, an inducer of heat shock protein 70, attenuates pulmonary fibrosis via inhibiting NF-κB/NOX4/ROS signalling pathway in vitro and in vivoChemico-Biological Interactions, 2023
- N-methylpiperazine-diepoxyovatodiolide ameliorates peritoneal fibrosis via suppressing TGF-β/Smad and JAK/STAT signaling pathwayChemico-Biological Interactions, 2023
- Changes in oxidative markers in COVID-19 patientsArchives of Medical Research, 2021
- COVID-19 patients’ sera induce epithelial mesenchymal transition in cancer cellsCancer Treatment and Research Communications, 2021
- Origin of Myofibroblasts in Lung FibrosisCurrent Tissue Microenvironment Reports, 2020